| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal ID2697: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies |
|
Medicine details |
|
| Medicine name | trastuzumab deruxtecan (Enhertu®) |
| Formulation | intravenous infusion |
| Reference number | 4126 |
| Indication | Treatment of adults with HER2-positive, unresectable and/or metastatic breast cancer who have previously received two or more anti-HER2 therapies |
| Company | Daiichi Sankyo UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 15/02/2021 |
| NICE guidance | |